lipid-lowering therapy


Also found in: Acronyms.

lipid-lowering therapy

drugs, dietary and lifestyle regimes directed toward restoring blood lipids to normal levels
References in periodicals archive ?
Currently, WOSCOPS and AFCAPS/TexCAPS are the only major primary prevention trials of lipid-lowering therapy in elderly populations.
Data Source: A meta-analysis involving 44,255 patients in eight clinical trials of lipid-lowering therapy.
All of these results were adjusted only for age and sex; however, similar results were seen when we additionally adjusted for lipid-lowering therapy (data not shown).
There is recent clinical and experimental evidence that lipid-lowering therapy, such as statins, can restore normal heart rhythms, thus helping to prevent sudden death," Dr.
In contrast, the AF patients on lipid-lowering therapy demonstrated significant improvement over baseline in speed of information processing, memory, and executive function as assessed by switching tests.
Although lipid-lowering therapies, including statins, may lower Lp-PLA2 levels, pharmacologic interventions are now being studied to find ways of best inhibiting the Lp-PLA2 enzyme and potentially providing incremental benefit to intensive lipid-lowering therapy.
Low-density lipoprotein cholesterol (LDL-C) is the primary target of lipid-lowering therapy, as the link between LDL-C and CAD is well established.
In addition, only half of the women who met the criteria of the National Cholesterol Program II guidelines for lipid-lowering therapy were taking statins or other lipid-lowering treatments at enrollment (Ann.
The sub analysis showed a 47 per cent reduction in LDL-C levels among stable coronary artery disease (CAD) patients who remained event-free following aggressive lipid-lowering therapy with LIPITOR(R) (atorvastatin calcium).
Senior Research Manager at Express Scripts, showed that physicians' use of Corus CAD was associated with increased medication adherence among patients prescribed lipid-lowering therapy.
Individuals are then stratified into low risk (< 10% risk over 10 years), intermediate risk (10% to 20% risk over 10 years), or high -risk (>20% risk over 10 years) based on their score (1), and this risk score then guides a clinician's decision to institute antiplatelet or lipid-lowering therapy or advise intensive lifestyle modification.
Although there is room for improvement, particularly in very high-risk patients, these results indicate that lipid-lowering therapy is being applied much more successfully than it was a decade ago," said David D.